TPM3
TPM3 (tropomyosin 3, also known as TRK or NEM1) encodes tropomyosin alpha-3 chain, an actin-binding protein of the tropomyosin family. It binds actin filaments in muscle and non-muscle cells, where it contributes to filament stability and to the regulation of muscle contraction. Browse Assay Genie's current range of TPM3 research reagents below, or read on for the biology behind the target.
TPM3 is a member of the tropomyosin family of actin-binding proteins. Tropomyosins are dimers of coiled-coil proteins that stabilise actin filaments and regulate access of other actin-binding proteins to them. In striated muscle, the tropomyosin alpha-3 chain works with the troponin complex in the calcium-dependent regulation of contraction. In smooth muscle, contraction is regulated through its interaction with caldesmon. In non-muscle cells it is implicated in stabilising cytoskeletal actin filaments.
The TPM3 gene is classed by HGNC in the tropomyosins group. The protein is found in the cytoplasm as part of the cytoskeleton. Alternative splicing of the gene produces multiple transcript variants, and numerous pseudogenes are found on other chromosomes, which is worth bearing in mind when designing nucleic acid-based experiments. Mouse and rat each carry an orthologous Tpm3 gene.
TPM3 is relevant to both muscle disease and cancer biology. Mutations in the gene cause autosomal dominant nemaline myopathy and other muscle disorders, which accounts for the alias NEM1. The locus is also involved in translocations with anaplastic lymphoma receptor tyrosine kinase (ALK) and neurotrophic tyrosine kinase receptor type 1 (NTRK1). These produce fusion proteins that act as oncogenes, and the alias TRK reflects the NTRK1 connection. Researchers studying TPM3 therefore work across cytoskeletal biology, myopathy and oncogenic fusion signalling.
TPM3 binds actin filaments and is implicated in stabilising cytoskeletal actin filaments in non-muscle cells, making it a useful subject for filament dynamics studies.
Together with the troponin complex, tropomyosin alpha-3 chain contributes to calcium-dependent regulation of striated muscle contraction; smooth muscle regulation involves caldesmon.
Mutations in TPM3 result in autosomal dominant nemaline myopathy and other muscle disorders, so the gene is central to myopathy research.
TPM3 translocations with ALK and NTRK1 generate fusion proteins that act as oncogenes, linking this cytoskeletal gene to cancer research.
TPM3 encodes tropomyosin alpha-3 chain, which binds actin filaments in muscle and non-muscle cells. With the troponin complex it helps regulate calcium-dependent striated muscle contraction, and in non-muscle cells it is implicated in stabilising actin filaments. Smooth muscle contraction is regulated through caldesmon.
TPM3 is also known as TRK and NEM1, and the protein is called tropomyosin alpha-3 chain. Alternative splicing gives rise to multiple transcript variants. Numerous pseudogenes exist on other chromosomes, so check the datasheet of any product for its validated reactivity and target specificity.
Yes. TPM3 mutations cause autosomal dominant nemaline myopathy and other muscle disorders, and translocations with ALK or NTRK1 create oncogenic fusion proteins. Mouse and rat both have an orthologous Tpm3 gene; check the datasheet of any product for its validated reactivity.
Other tropomyosin family members and related targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P06753; product specifications from Assay Genie datasheets.